-
公开(公告)号：US20180312805A1
公开(公告)日：2018-11-01
申请号：US15771046
申请日：2016-10-26
Inventor： Benjamin Eithan REUBINOFF , Orna SINGER , Osnat BOHANA-KASHTAN , Ofer WISER
IPC: C12N5/079 , C12N5/0735 , C12N5/00
CPC classification number: C12N5/0621 , C12N2501/15 , C12N2501/16 , C12N2506/02 , C12N2533/52
Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
-
92.发明授权公开(公告)号：US09981037B2
公开(公告)日：2018-05-29
申请号：US14183248
申请日：2014-02-18
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , The Brigham and Women's Hospital, Inc.
Inventor： Yaron Ilan , Howard L. Weiner
IPC: A61K39/395 , A61K31/7032 , A61K45/06 , C07K16/28 , A61K31/7028
CPC classification number: A61K39/3955 , A61K31/7028 , A61K31/7032 , A61K45/06 , C07K16/2809 , A61K2300/00
Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
-
公开(公告)号：US09957314B2
公开(公告)日：2018-05-01
申请号：US14471262
申请日：2014-08-28
Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services and Development Ltd.
Inventor： Dan Deutsch , Amir Haze , Anat Blumenfeld
Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
-
公开(公告)号：US09797911B2
公开(公告)日：2017-10-24
申请号：US14304948
申请日：2014-06-15
Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services and Development Ltd.
Inventor： Eli Keshet , Shay Sela , Ahuva Itin , Simcha Yagel
CPC classification number: G01N33/689 , C07K14/71
Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
-
公开(公告)号：US20170224783A1
公开(公告)日：2017-08-10
申请号：US15429132
申请日：2017-02-09
Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. , Hadasit Medical Research Services and Development Ltd.
Inventor： Haya Galski-Lorberboum , Matan Rapoport , Orly Elpeleg , Ann Saada
IPC: A61K38/44
CPC classification number: A61K38/44 , C07K2319/07 , C07K2319/10 , C12N9/0051 , C12N2740/16011 , C12Y108/01004
Abstract: The present invention concerns in general novel fusion proteins comprising a membrane transferring moiety and an enzymatic moiety. The present invention further concerns a method of treating disease using said fusion proteins.
-
Patent Agency Ranking
公开(公告)号：US09616067B2
公开(公告)日：2017-04-11
申请号：US14394973
申请日：2013-04-17
Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventor： Richard K. Haynes , Dana G. Wolf
IPC: A61K31/54 , A61K31/541 , A61K31/357 , C07D493/18 , A61K45/06 , A61K31/522
CPC classification number: A61K31/541 , A61K31/357 , A61K31/522 , A61K45/06 , C07D493/18 , A61K2300/00
Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
-
97.发明申请MIR-122* AS AN ACTIVE MICRO-RNA, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF 审中-公开MIR-122 *作为活性微RNA，包含其的组合物及其用途公开(公告)号：US20160333344A1
公开(公告)日：2016-11-17
申请号：US15109879
申请日：2015-01-06
Inventor： Hilla GILADI , Alina SIMERZIN , Yael HANTZ , Sagit ARBEL ALON , Eithan GALUN
IPC: C12N15/113 , A61K45/06 , A61K31/7088
CPC classification number: C12N15/113 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N2310/141 , C12N2320/30 , C12N2320/31 , A61K2300/00
Abstract: Provided is a miR-122* as a functional microRNA molecule, compositions including the same and uses thereof for treatment of various conditions, such as, cancer.
Abstract translation: 提供了作为功能性微小RNA分子的miR-122 *，包含其的组合物及其用于治疗各种病症如癌症的用途。
-
98.发明授权Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD) 有权NLGn4表达的调节，非酒精性脂肪性肝病（NAFLD）中的NK细胞活性公开(公告)号：US09469855B2
公开(公告)日：2016-10-18
申请号：US14963319
申请日：2015-12-09
Inventor： Rifaat Safadi
IPC: A61K48/00 , C07H21/02 , C07H21/04 , C12N15/113 , A61K31/7088 , A61K45/06 , C12Q1/68 , A61K31/713 , A61K31/7105
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
Abstract translation: 本发明提供通过抑制NGn4表达从而调节NK细胞的活性来治疗，减轻或预防肝脏疾病的方法。 本发明还涉及通过评估NK细胞中的NLGn4表达来诊断肝脏疾病。
-
99.发明申请DEVICES AND METHODS FOR PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AND OTHER OSTOMY PROCEDURES 审中-公开胰腺内分泌肿瘤和其他方法的装置和方法公开(公告)号：US20160143816A1
公开(公告)日：2016-05-26
申请号：US14900160
申请日：2014-06-19
Inventor： Ishay BENURI-SILBIGER
IPC: A61J15/00
Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
Abstract translation: 提供了具有改进的保持装置的造口管，特别是胃造口术管。 更具体地，提供了用于胃造口管的保留结构，例如枕垫，构造成可移除地组装到胃造口管的一端以促进管的更换和移除。 本文提供的保持结构可以包括一个或多个可拆卸地组装的保持元件。 还提供了包括这种保留结构的胃造口术管，以及利用其的经皮内窥镜胃造口术的方法。
-
100.发明申请MODULATION OF NLGn4 EXPRESSION, NK CELL ACTIVITY IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 有权NLGn4表达的调节，非酒精性脂肪肝疾病（NAFLD）中的NK细胞活性公开(公告)号：US20160115485A1
公开(公告)日：2016-04-28
申请号：US14963319
申请日：2015-12-09
Inventor： Rifaat SAFADI
IPC: C12N15/113
CPC classification number: C12Q1/6883 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q2600/158
Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
Abstract translation: 本发明提供通过抑制NGn4表达从而调节NK细胞的活性来治疗，减轻或预防肝脏疾病的方法。 本发明还涉及通过评估NK细胞中的NLGn4表达来诊断肝脏疾病。
-
-
-
-
-
-
-
-
-
Search Results
180
records
(took 0.037 seconds)
